MYC and myelodysplastic syndrome: Although no MYC-targeting compounds have yet entered clinical trials, APTO-253, which partially reduces MYC expression, is currently undergoing phase I trials for relapsed or refractory AML or myelodysplastic syndromes (NCT02267863) [37].